Equities

Amarin Corporation PLC

Amarin Corporation PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.5748
  • Today's Change-0.001 / -0.12%
  • Shares traded837.58k
  • 1 Year change-23.95%
  • Beta1.8776
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments321309454
Total Receivables, Net134131164
Total Inventory259229235
Prepaid expenses121922
Other current assets, total0.530.523.92
Total current assets725689879
Property, plant & equipment, net8.429.959.09
Goodwill, net------
Intangibles, net192224
Long term investments01.2835
Note receivable - long term------
Other long term assets79164122
Total assets8328861,068
LIABILITIES
Accounts payable5365115
Accrued expenses179157208
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total283848
Total current liabilities259259371
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total203130
Total liabilities280291401
SHAREHOLDERS EQUITY
Common stock303299294
Additional paid-in capital1,8991,8851,855
Retained earnings (accumulated deficit)(1586)(1527)(1421)
Treasury stock - common(64)(62)(61)
Unrealized gain (loss)------
Other equity, total------
Total equity552595667
Total liabilities & shareholders' equity8328861,068
Total common shares outstanding409404397
Treasury shares - common primary issue9.327.997.49
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.